1
|
White-matter free-water diffusion MRI in schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2022; 47:1413-1420. [PMID: 35034098 PMCID: PMC9117206 DOI: 10.1038/s41386-022-01272-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Revised: 12/09/2021] [Accepted: 01/05/2022] [Indexed: 11/08/2022]
Abstract
White-matter abnormalities, including increases in extracellular free-water, are implicated in the pathophysiology of schizophrenia. Recent advances in diffusion magnetic resonance imaging (MRI) enable free-water levels to be indexed. However, the brain levels in patients with schizophrenia have not yet been systematically investigated. We aimed to meta-analyse white-matter free-water levels in patients with schizophrenia compared to healthy volunteers. We performed a literature search in EMBASE, MEDLINE, and PsycINFO databases. Diffusion MRI studies reporting free-water in patients with schizophrenia compared to healthy controls were included. We investigated the effect of demographic variables, illness duration, chlorpromazine equivalents of antipsychotic medication, type of scanner, and clinical symptoms severity on free-water measures. Ten studies, including five of first episode of psychosis have investigated free-water levels in schizophrenia, with significantly higher levels reported in whole-brain and specific brain regions (including corona radiata, internal capsule, superior and inferior longitudinal fasciculus, cingulum bundle, and corpus callosum). Six studies, including a total of 614 participants met the inclusion criteria for quantitative analysis. Whole-brain free-water levels were significantly higher in patients relative to healthy volunteers (Hedge's g = 0.38, 95% confidence interval (CI) 0.07-0.69, p = 0.02). Sex moderated this effect, such that smaller effects were seen in samples with more females (z = -2.54, p < 0.05), but antipsychotic dose, illness duration and symptom severity did not. Patients with schizophrenia have increased free-water compared to healthy volunteers. Future studies are necessary to determine the pathological sources of increased free-water, and its relationship with illness duration and severity.
Collapse
|
2
|
Dinesh AA, Islam J, Khan J, Turkheimer F, Vernon AC. Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System. CNS Drugs 2020; 34:1229-1251. [PMID: 32975758 DOI: 10.1007/s40263-020-00765-x] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/29/2020] [Indexed: 12/11/2022]
Abstract
Converging lines of evidence suggest that activation of microglia (innate immune cells in the central nervous system [CNS]) is present in a subset of patients with schizophrenia. The extent to which antipsychotic drug treatment contributes to or combats this effect remains unclear. To address this question, we reviewed the literature for evidence that antipsychotic exposure influences brain microglia as indexed by in vivo neuroimaging and post-mortem studies in patients with schizophrenia and experimental animal models. We found no clear evidence from clinical studies for an effect of antipsychotics on either translocator protein (TSPO) radioligand binding (an in vivo neuroimaging measure of putative gliosis) or markers of brain microglia in post-mortem studies. In experimental animals, where drug and illness effects may be differentiated, we also found no clear evidence for consistent effects of antipsychotic drugs on TSPO radioligand binding. By contrast, we found evidence that chronic antipsychotic exposure may influence central microglia density and morphology. However, these effects were dependent on the dose and duration of drug exposure and whether an immune stimulus was present or not. In the latter case, antipsychotics were generally reported to suppress expression of inflammatory cytokines and inducible inflammatory enzymes such as cyclooxygenase and microglia activation. No clear conclusions could be drawn with regard to any effect of antipsychotics on brain microglia from current clinical data. There is evidence to suggest that antipsychotic drugs influence brain microglia in experimental animals, including possible anti-inflammatory actions. However, we lack detailed information on how these drugs influence brain microglia function at the molecular level. The clinical relevance of the animal data with regard to beneficial treatment effects and detrimental side effects of antipsychotic drugs also remains unknown, and further studies are warranted.
Collapse
Affiliation(s)
- Ayushi Anna Dinesh
- School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - Juned Islam
- School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - Javad Khan
- School of Medicine, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
| | - Federico Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Centre for Neuroimaging Sciences, De Crespigny Park, London, SE5 8AF, United Kingdom
- MRC Centre for Neurodevelopmental Disorders, King's College London, London, SE1 1UL, United Kingdom
| | - Anthony C Vernon
- MRC Centre for Neurodevelopmental Disorders, King's College London, London, SE1 1UL, United Kingdom.
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London, SE5 9RT, United Kingdom.
| |
Collapse
|
3
|
Zito MF, Marder SR. Rethinking the risks and benefits of long-term maintenance in schizophrenia. Schizophr Res 2020; 225:77-81. [PMID: 31806525 DOI: 10.1016/j.schres.2019.10.057] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 10/28/2019] [Accepted: 10/30/2019] [Indexed: 11/26/2022]
Abstract
This review addresses the risks and benefits of long-term maintenance antipsychotic treatment for patients that extends beyond two years. It focuses on framing discussions with patients who are recovering from a first episode. For these patients the evidence strongly supports the benefits over the risk for the first two years. However, both the clinical side effects of antipsychotics and the possible long-term effects of dopamine blocking drugs on the brain require a more nuanced discussion beyond this initial period. In most cases, the decision will be to continue antipsychotics but to consider strategies for mitigating the risks of drugs. This review provides information about the relative risks of dose reduction and intermittent treatment.
Collapse
Affiliation(s)
- Michael F Zito
- Semel Institute for Neuroscience at UCLA and the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, USA
| | - Stephen R Marder
- Semel Institute for Neuroscience at UCLA and the VA Desert Pacific Mental Illness Research, Education, and Clinical Center, Los Angeles, USA.
| |
Collapse
|
4
|
Haukvik UK, Gurholt TP, Nerland S, Elvsåshagen T, Akudjedu TN, Alda M, Alnæs D, Alonso‐Lana S, Bauer J, Baune BT, Benedetti F, Berk M, Bettella F, Bøen E, Bonnín CM, Brambilla P, Canales‐Rodríguez EJ, Cannon DM, Caseras X, Dandash O, Dannlowski U, Delvecchio G, Díaz‐Zuluaga AM, Erp TGM, Fatjó‐Vilas M, Foley SF, Förster K, Fullerton JM, Goikolea JM, Grotegerd D, Gruber O, Haarman BCM, Haatveit B, Hajek T, Hallahan B, Harris M, Hawkins EL, Howells FM, Hülsmann C, Jahanshad N, Jørgensen KN, Kircher T, Krämer B, Krug A, Kuplicki R, Lagerberg TV, Lancaster TM, Lenroot RK, Lonning V, López‐Jaramillo C, Malt UF, McDonald C, McIntosh AM, McPhilemy G, Meer D, Melle I, Melloni EMT, Mitchell PB, Nabulsi L, Nenadić I, Oertel V, Oldani L, Opel N, Otaduy MCG, Overs BJ, Pineda‐Zapata JA, Pomarol‐Clotet E, Radua J, Rauer L, Redlich R, Repple J, Rive MM, Roberts G, Ruhe HG, Salminen LE, Salvador R, Sarró S, Savitz J, Schene AH, Sim K, Soeiro‐de‐Souza MG, Stäblein M, Stein DJ, Stein F, Tamnes CK, Temmingh HS, Thomopoulos SI, Veltman DJ, Vieta E, Waltemate L, Westlye LT, Whalley HC, Sämann PG, Thompson PM, Ching CRK, Andreassen OA, Agartz I. In vivo hippocampal subfield volumes in bipolar disorder—A mega‐analysis from The Enhancing Neuro Imaging Genetics through
Meta‐Analysis
Bipolar Disorder Working Group. Hum Brain Mapp 2020; 43:385-398. [PMID: 33073925 PMCID: PMC8675404 DOI: 10.1002/hbm.25249] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 09/18/2020] [Accepted: 10/06/2020] [Indexed: 01/02/2023] Open
Abstract
The hippocampus consists of anatomically and functionally distinct subfields that may be differentially involved in the pathophysiology of bipolar disorder (BD). Here we, the Enhancing NeuroImaging Genetics through Meta‐Analysis Bipolar Disorder workinggroup, study hippocampal subfield volumetry in BD. T1‐weighted magnetic resonance imaging scans from 4,698 individuals (BD = 1,472, healthy controls [HC] = 3,226) from 23 sites worldwide were processed with FreeSurfer. We used linear mixed‐effects models and mega‐analysis to investigate differences in hippocampal subfield volumes between BD and HC, followed by analyses of clinical characteristics and medication use. BD showed significantly smaller volumes of the whole hippocampus (Cohen's d = −0.20), cornu ammonis (CA)1 (d = −0.18), CA2/3 (d = −0.11), CA4 (d = −0.19), molecular layer (d = −0.21), granule cell layer of dentate gyrus (d = −0.21), hippocampal tail (d = −0.10), subiculum (d = −0.15), presubiculum (d = −0.18), and hippocampal amygdala transition area (d = −0.17) compared to HC. Lithium users did not show volume differences compared to HC, while non‐users did. Antipsychotics or antiepileptic use was associated with smaller volumes. In this largest study of hippocampal subfields in BD to date, we show widespread reductions in nine of 12 subfields studied. The associations were modulated by medication use and specifically the lack of differences between lithium users and HC supports a possible protective role of lithium in BD.
Collapse
Affiliation(s)
- Unn K. Haukvik
- Department of Adult Mental Health Institute of Clinical Medicine, University of Oslo Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
| | - Tiril P. Gurholt
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
| | - Stener Nerland
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
| | - Torbjørn Elvsåshagen
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Department of Neurology Oslo University Hospital Oslo Norway
- Institute of Clinical Medicine University of Oslo Oslo Norway
| | - Theophilus N. Akudjedu
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
- Institute of Medical Imaging & Visualisation Faculty of Health & Social Sciences, Bournemouth University Bournemouth UK
| | - Martin Alda
- Department of Psychiatry Dalhousie University Halifax Nova Scotia Canada
- National Institute of Mental Health Klecany Czech Republic
| | - Dag Alnæs
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
| | - Silvia Alonso‐Lana
- FIDMAG Germanes Hospitalàries Research Foundation CIBERSAM Barcelona Spain
| | - Jochen Bauer
- Institute of Clinical Radiology University of Münster Münster Germany
| | - Bernhard T. Baune
- Department of Psychiatry University of Münster Münster Germany
- Department of Psychiatry Melbourne Medical School, The University of Melbourne Melbourne Australia
- The Florey Institute of Neuroscience and Mental Health The University of Melbourne Parkville Australia
| | - Francesco Benedetti
- Psychiatry and Clinical Psychobiology Scientific Institute Ospedale San Raffaele Milan Italy
- University Vita‐Salute San Raffaele Milan Italy
| | - Michael Berk
- Deakin University IMPACT, the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health Geelong Victoria Australia
- Orygen, The National Centre of Excellence in Youth Mental Health and Centre for Youth Mental Health, the Department of Psychiatry and the Florey Institute for Neuroscience and Mental Health The University of Melbourne Melbourne Victoria Australia
| | - Francesco Bettella
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
| | - Erlend Bøen
- Psychosomatic and CL Psychiatry Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
| | - Caterina M. Bonnín
- Barcelona Bipolar Disorders and Depressive Unit Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM Barcelona Spain
| | - Paolo Brambilla
- Department of Neurosciences and Mental Health Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
- Department of Pathophysiology and Transplantation University of Milan Milan Italy
| | | | - Dara M. Cannon
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
| | - Xavier Caseras
- MRC Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Clinical Neurosciences Cardiff University Cardiff UK
| | - Orwa Dandash
- Brain, Mind and Society Research Hub, Turner Institute for Brain and Mental Health, School of Psychological Sciences Monash University Clayton Victoria Australia
- Melbourne Neuropsychiatry Centre, Department of Psychiatry University of Melbourne and Melbourne Health Melbourne Victoria Australia
| | - Udo Dannlowski
- Department of Psychiatry University of Münster Münster Germany
| | - Giuseppe Delvecchio
- Department of Pathophysiology and Transplantation University of Milan Milan Italy
| | - Ana M. Díaz‐Zuluaga
- Research Group in Psychiatry, Department of Psychiatry Faculty of Medicine, Universidad de Antioquia Medellín Antioquia Colombia
| | - Theo G. M. Erp
- Clinical Translational Neuroscience Laboratory, Department of Psychiatry and Human Behavior University of California Irvine Irvine California USA
- Center for the Neurobiology of Learning University of California Irvine and Memory Irvine California USA
| | - Mar Fatjó‐Vilas
- FIDMAG Germanes Hospitalàries Research Foundation CIBERSAM Barcelona Spain
| | - Sonya F. Foley
- Cardiff University Brain Research Imaging Centre (CUBRIC) Cardiff University Cardiff UK
| | | | - Janice M. Fullerton
- Neuroscience Research Australia Randwick New South Wales Australia
- School of Medical Sciences The University of New South Wales Sydney New South Wales Australia
| | - José M. Goikolea
- Barcelona Bipolar Disorders and Depressive Unit Hospital Clinic, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM Barcelona Spain
| | | | - Oliver Gruber
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry Heidelberg University Hospital Heidelberg Germany
| | - Bartholomeus C. M. Haarman
- Department of Psychiatry University Medical Center Groningen, University of Groningen Groningen The Netherlands
| | - Beathe Haatveit
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
| | - Tomas Hajek
- Department of Psychiatry Dalhousie University Halifax Nova Scotia Canada
- National Institute of Mental Health Klecany Czech Republic
| | - Brian Hallahan
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
| | - Mathew Harris
- Division of Psychiatry University of Edinburgh Edinburgh UK
| | | | - Fleur M. Howells
- Department of Psychiatry and Mental Health University of Cape Town Cape Town Western Cape South Africa
- Neuroscience Institute University of Cape Town Cape Town Western Cape South Africa
| | - Carina Hülsmann
- Department of Psychiatry University of Münster Münster Germany
| | - Neda Jahanshad
- Imaging Genetics Center USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California Marina del Rey California USA
| | - Kjetil N. Jørgensen
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
| | - Tilo Kircher
- Department of Psychiatry and Psychotherapy Philipps‐University Marburg Marburg Germany
- Center for Mind Brain and Behavior (CMBB) Marburg Germany
| | - Bernd Krämer
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry Heidelberg University Hospital Heidelberg Germany
| | - Axel Krug
- Department of Psychiatry and Psychotherapy Philipps‐University Marburg Marburg Germany
- Center for Mind Brain and Behavior (CMBB) Marburg Germany
- Department of Psychiatry and Psychotherapy University of Bonn Bonn Germany
| | - Rayus Kuplicki
- Laureate Institute for Brain Research Tulsa Oklahoma USA
| | - Trine V. Lagerberg
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
| | - Thomas M. Lancaster
- Cardiff University Brain Research Imaging Centre (CUBRIC) Cardiff University Cardiff UK
- School of Psychology Bath University Bath UK
| | - Rhoshel K. Lenroot
- Neuroscience Research Australia Randwick New South Wales Australia
- School of Psychiatry University of New South Wales Sydney New South Wales Australia
- University of New Mexico Albuquerque New Mexico USA
| | - Vera Lonning
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
| | - Carlos López‐Jaramillo
- Research Group in Psychiatry, Department of Psychiatry Faculty of Medicine, Universidad de Antioquia Medellín Antioquia Colombia
- Mood Disorders Program Hospital Universitario San Vicente Fundación Medellín Antioquia Colombia
| | - Ulrik F. Malt
- Institute of Clinical Medicine University of Oslo Oslo Norway
| | - Colm McDonald
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
| | | | - Genevieve McPhilemy
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
| | - Dennis Meer
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- School of Mental Health and Neuroscience Faculty of Health, Medicine and Life Sciences, Maastricht University Maastricht The Netherlands
| | - Ingrid Melle
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
| | - Elisa M. T. Melloni
- Psychiatry and Clinical Psychobiology Scientific Institute Ospedale San Raffaele Milan Italy
- University Vita‐Salute San Raffaele Milan Italy
| | - Philip B. Mitchell
- School of Psychiatry University of New South Wales Sydney New South Wales Australia
- Black Dog Institute Sydney New South Wales Australia
| | - Leila Nabulsi
- Centre for Neuroimaging & Cognitive Genomics (NICOG) Clinical Neuroimaging Laboratory, NCBES Galway Neuroscience Centre, College of Medicine Nursing and Health Sciences, National University of Ireland Galway Galway Ireland
| | - Igor Nenadić
- Department of Psychiatry and Psychotherapy Philipps‐University Marburg Marburg Germany
- Center for Mind Brain and Behavior (CMBB) Marburg Germany
| | - Viola Oertel
- Department of Psychiatry Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt Frankfurt am Main Germany
| | - Lucio Oldani
- Department of Neurosciences and Mental Health Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
| | - Nils Opel
- Department of Psychiatry University of Münster Münster Germany
| | - Maria C. G. Otaduy
- LIM44, Department of Radiology and Oncology University of São Paulo São Paulo Brazil
| | - Bronwyn J. Overs
- Neuroscience Research Australia Randwick New South Wales Australia
| | - Julian A. Pineda‐Zapata
- Research Group in Psychiatry, Department of Psychiatry Faculty of Medicine, Universidad de Antioquia Medellín Antioquia Colombia
- Research Group Instituto de Alta Tecnología Médica Medellín Antioquia Colombia
| | | | - Joaquim Radua
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM Barcelona Spain
- Department of Psychosis Studies Institute of Psychiatry, Psychology and Neuroscience, King's College London London UK
- Department of Clinical Neuroscience Centre for Psychiatry Research, Karolinska Institutet Stockholm Sweden
| | - Lisa Rauer
- Section for Experimental Psychopathology and Neuroimaging, Department of General Psychiatry Heidelberg University Hospital Heidelberg Germany
| | - Ronny Redlich
- Department of Psychiatry University of Münster Münster Germany
| | - Jonathan Repple
- Department of Psychiatry University of Münster Münster Germany
| | - Maria M. Rive
- Psychiatry Amsterdam UMC, Location AMC Amsterdam The Netherlands
| | - Gloria Roberts
- School of Psychiatry University of New South Wales Sydney New South Wales Australia
- Black Dog Institute Sydney New South Wales Australia
| | - Henricus G. Ruhe
- Psychiatry Amsterdam UMC, Location AMC Amsterdam The Netherlands
- Donders Institute for Brain, Cognition and Behavior Radboud University Nijmegen The Netherlands
- Department of Psychiatry Radboudumc Nijmegen The Netherlands
| | - Lauren E. Salminen
- Imaging Genetics Center USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California Marina del Rey California USA
| | - Raymond Salvador
- FIDMAG Germanes Hospitalàries Research Foundation CIBERSAM Barcelona Spain
| | - Salvador Sarró
- FIDMAG Germanes Hospitalàries Research Foundation CIBERSAM Barcelona Spain
| | - Jonathan Savitz
- Laureate Institute for Brain Research Tulsa Oklahoma USA
- Oxley College of Health Sciences The University of Tulsa Tulsa Oklahoma USA
| | - Aart H. Schene
- Donders Institute for Brain, Cognition and Behavior Radboud University Nijmegen The Netherlands
- Department of Psychiatry Radboudumc Nijmegen The Netherlands
| | - Kang Sim
- West Region/Institute of Mental Health Singapore Singapore
- Yong Loo Lin School of Medicine/National University of Singapore Singapore Singapore
- Lee Kong Chian School of Medicine/Nanyang Technological University Singapore Singapore
| | | | - Michael Stäblein
- Department of Psychiatry Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt Frankfurt am Main Germany
| | - Dan J. Stein
- Department of Psychiatry and Mental Health University of Cape Town Cape Town Western Cape South Africa
- Neuroscience Institute University of Cape Town Cape Town Western Cape South Africa
- SA MRC Unit on Risk & Resilience in Mental Disorders, Department of Psychiatry & Neuroscience Institute University of Cape Town Cape Town Western Cape South Africa
| | - Frederike Stein
- Department of Psychiatry and Psychotherapy Philipps‐University Marburg Marburg Germany
- Center for Mind Brain and Behavior (CMBB) Marburg Germany
| | - Christian K. Tamnes
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
- PROMENTA Research Center, Department of Psychology University of Oslo Oslo Norway
| | - Henk S. Temmingh
- Department of Psychiatry and Mental Health University of Cape Town Cape Town Western Cape South Africa
- General Adult Psychiatry Division Valkenberg Hospital Cape Town Western Cape South Africa
| | - Sophia I. Thomopoulos
- Imaging Genetics Center USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California Marina del Rey California USA
| | - Dick J. Veltman
- Department of Psychiatry Amsterdam UMC, Location VUMC Amsterdam The Netherlands
- Amsterdam Neuroscience Amsterdam UMC Amsterdam The Netherlands
| | - Eduard Vieta
- Hospital Clinic University of Barcelona, IDIBAPS, CIBERSAM Barcelona Catalonia Spain
| | - Lena Waltemate
- Department of Psychiatry University of Münster Münster Germany
| | - Lars T. Westlye
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Department of Psychology University of Oslo Oslo Norway
| | | | | | - Paul M. Thompson
- Imaging Genetics Center USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California Marina del Rey California USA
| | - Christopher R. K. Ching
- Imaging Genetics Center USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine of the University of Southern California Marina del Rey California USA
| | - Ole A. Andreassen
- Norwegian Centre for Mental Disorders Research (NORMENT) Division of Mental Health and Addiction, Oslo University Hospital Oslo Norway
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
| | - Ingrid Agartz
- Norwegian Centre for Mental Disorders Research (NORMENT) Institute of Clinical Medicine, University of Oslo Oslo Norway
- Department of Psychiatric Research Diakonhjemmet Hospital Oslo Norway
- Department of Clinical Neuroscience Centre for Psychiatric Research, Karolinska Institutet Stockholm Sweden
| | | |
Collapse
|
5
|
The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted. Int J Mol Sci 2020; 21:ijms21155555. [PMID: 32756473 PMCID: PMC7432375 DOI: 10.3390/ijms21155555] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/28/2020] [Accepted: 07/31/2020] [Indexed: 02/07/2023] Open
Abstract
Background: Antipsychotic agents modulate key molecules of the postsynaptic density (PSD), including the Homer1a gene, implicated in dendritic spine architecture. How the antipsychotic receptor profile, dose, and duration of administration may influence synaptic plasticity and the Homer1a pattern of expression is yet to be determined. Methods: In situ hybridization for Homer1a was performed on rat tissue sections from cortical and striatal regions of interest (ROI) after acute or chronic administration of three antipsychotics with divergent receptor profile: Haloperidol, asenapine, and olanzapine. Univariate and multivariate analyses of the effects of topography, treatment, dose, and duration of antipsychotic administration were performed. Results: All acute treatment regimens were found to induce a consistently higher expression of Homer1a compared to chronic ones. Haloperidol increased Homer1a expression compared to olanzapine in striatum at the acute time-point. A dose effect was also observed for acute administration of haloperidol. Conclusions: Biological effects of antipsychotics on Homer1a varied strongly depending on the combination of their receptor profile, dose, duration of administration, and throughout the different brain regions. These molecular data may have translational valence and may reflect behavioral sensitization/tolerance phenomena observed with prolonged antipsychotics.
Collapse
|
6
|
Luo C, Wang X, Mao X, Huang H, Liu Y, Zhao J, Zhou H, Liu Z, Li X. Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. Psychopharmacology (Berl) 2020; 237:2257-2277. [PMID: 32588080 DOI: 10.1007/s00213-020-05524-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Accepted: 04/08/2020] [Indexed: 12/14/2022]
Abstract
RATIONALE Second-generation antipsychotics are the first-line medications prescribed for schizophrenic patients; however, some of them, such as olanzapine and risperidone, may induce metabolic dysfunctions during short-term treatment. Metformin is an effective adjuvant that attenuates antipsychotic-induced metabolic dysfunctions (AIMD) in clinical practice. Whether metformin can reverse AIMD and whether metformin affects the therapeutic effects of antipsychotics in animal models of schizophrenia are questions that still need to be investigated. METHODS In this study, an animal model of schizophrenia was established by consecutive injections of MK801 during the neurodevelopmental period. In adulthood, different dosages of olanzapine or risperidone treatment were administered to the schizophrenia model animals for 14 days. Both therapeutic effects and metabolic adverse effects were measured by behavioral tests, histopathological tests, and biochemical tests. The coadministration of different doses of metformin with olanzapine or risperidone was used to evaluate the effects of metformin on both AIMD and the therapeutic effect of those antipsychotics. RESULTS The MK801-treated rats showed schizophrenia-like behavior and variations in the shape and volume of the hippocampus. Both olanzapine and risperidone reversed the MK801-induced behavioral abnormalities as the dosage increased; however, they degenerated the hepatocytes in the liver and influenced the blood lipid levels and blood glucose levels. The coadministration of metformin did not affect the therapeutic effects of olanzapine or risperidone on behavioral abnormalities but attenuated the metabolic dysfunctions induced by those antipsychotics. CONCLUSION Metformin attenuated the olanzapine- and risperidone-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats without reducing the therapeutic effects of the antipsychotics.
Collapse
Affiliation(s)
- Chao Luo
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China
- School of Life Sciences, Central South University, Changsha, 410078, Hunan, China
| | - Xu Wang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China
| | - Xiaoyuan Mao
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China
| | - Hanxue Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China
| | - Yong Liu
- Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, No. 139, Renmin Middle Road, Changsha, 410011, China
| | - Jingping Zhao
- Mental Health Institute of the Second Xiangya Hospital, National Technology Institute of Psychiatry, Key Laboratory of Psychiatry and Mental Health of Hunan Province, Central South University, No. 139, Renmin Middle Road, Changsha, 410011, China
| | - Honghao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China
| | - Zhaoqian Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.
- Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha, 410078, China.
| | - Xiangping Li
- Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, 410008, China.
| |
Collapse
|
7
|
Turkheimer FE, Selvaggi P, Mehta MA, Veronese M, Zelaya F, Dazzan P, Vernon AC. Normalizing the Abnormal: Do Antipsychotic Drugs Push the Cortex Into an Unsustainable Metabolic Envelope? Schizophr Bull 2020; 46:484-495. [PMID: 31755955 PMCID: PMC7147598 DOI: 10.1093/schbul/sbz119] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The use of antipsychotic medication to manage psychosis, principally in those with a diagnosis of schizophrenia or bipolar disorder, is well established. Antipsychotics are effective in normalizing positive symptoms of psychosis in the short term (delusions, hallucinations and disordered thought). Their long-term use is, however, associated with side effects, including several types of movement (extrapyramidal syndrome, dyskinesia, akathisia), metabolic and cardiac disorders. Furthermore, higher lifetime antipsychotic dose-years may be associated with poorer cognitive performance and blunted affect, although the mechanisms driving the latter associations are not well understood. In this article, we propose a novel model of the long-term effects of antipsychotic administration focusing on the changes in brain metabolic homeostasis induced by the medication. We propose here that the brain metabolic normalization, that occurs in parallel to the normalization of psychotic symptoms following antipsychotic treatment, may not ultimately be sustainable by the cerebral tissue of some patients; these patients may be characterized by already reduced oxidative metabolic capacity and this may push the brain into an unsustainable metabolic envelope resulting in tissue remodeling. To support this perspective, we will review the existing data on the brain metabolic trajectories of patients with a diagnosis of schizophrenia as indexed using available neuroimaging tools before and after use of medication. We will also consider data from pre-clinical studies to provide mechanistic support for our model.
Collapse
Affiliation(s)
- Federico E Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
| | - Pierluigi Selvaggi
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Mitul A Mehta
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Fernando Zelaya
- Department of Neuroimaging, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Paola Dazzan
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| | - Anthony C Vernon
- MRC Centre for Neurodevelopmental Disorders, King’s College London, London, UK
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
| |
Collapse
|
8
|
Onwordi EC, Halff EF, Whitehurst T, Mansur A, Cotel MC, Wells L, Creeney H, Bonsall D, Rogdaki M, Shatalina E, Reis Marques T, Rabiner EA, Gunn RN, Natesan S, Vernon AC, Howes OD. Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nat Commun 2020; 11:246. [PMID: 31937764 PMCID: PMC6959348 DOI: 10.1038/s41467-019-14122-0] [Citation(s) in RCA: 135] [Impact Index Per Article: 33.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Accepted: 12/09/2019] [Indexed: 12/15/2022] Open
Abstract
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms and structural brain measures using [11C]UCB-J positron emission tomography in 18 patients with schizophrenia and 18 controls. We found significant group and group-by-region interaction effects on volume of distribution (VT). [11C]UCB-J VT was significantly lower in the frontal and anterior cingulate cortices in schizophrenia with large effect sizes (Cohen's d = 0.8-0.9), but there was no significant difference in the hippocampus. We also investigated the effects of antipsychotic drug administration on SV2A levels in Sprague-Dawley rats using western blotting, [3H]UCB-J autoradiography and immunostaining with confocal microscopy, finding no significant effects on any measure. These findings indicate that there are lower synaptic terminal protein levels in schizophrenia in vivo and that antipsychotic drug exposure is unlikely to account for them.
Collapse
Affiliation(s)
- Ellis Chika Onwordi
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
- South London and Maudsley NHS Foundation Trust, Camberwell, London, SE5 8AF, UK
| | - Els F Halff
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
| | - Thomas Whitehurst
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
- South London and Maudsley NHS Foundation Trust, Camberwell, London, SE5 8AF, UK
| | - Ayla Mansur
- Division of Brain Sciences, Imperial College London, The Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
| | - Marie-Caroline Cotel
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK
| | - Lisa Wells
- Invicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK
| | - Hannah Creeney
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK
| | - David Bonsall
- Invicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK
| | - Maria Rogdaki
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
- South London and Maudsley NHS Foundation Trust, Camberwell, London, SE5 8AF, UK
| | - Ekaterina Shatalina
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, W12 0NN, UK
| | - Tiago Reis Marques
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
- South London and Maudsley NHS Foundation Trust, Camberwell, London, SE5 8AF, UK
| | - Eugenii A Rabiner
- Invicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
| | - Roger N Gunn
- Division of Brain Sciences, Imperial College London, The Commonwealth Building, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
- Invicro Imaging Services, Burlington Danes Building, Du Cane Road, London, W12 0NN, UK
| | - Sridhar Natesan
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK
| | - Anthony C Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London, SE5 9RT, UK
- MRC Centre for Neurodevelopmental Disorders, King's College London, London, SE1 1UL, UK
| | - Oliver D Howes
- Psychiatric Imaging Group, MRC London Institute of Medical Sciences, Hammersmith Hospital, London, W12 0NN, UK.
- Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, W12 0NN, UK.
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, De Crespigny Park, London, SE5 8AF, UK.
- South London and Maudsley NHS Foundation Trust, Camberwell, London, SE5 8AF, UK.
| |
Collapse
|
9
|
Marques TR, Ashok AH, Pillinger T, Veronese M, Turkheimer FE, Dazzan P, Sommer IE, Howes OD. Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies. Psychol Med 2019; 49:2186-2196. [PMID: 30355368 PMCID: PMC6366560 DOI: 10.1017/s0033291718003057] [Citation(s) in RCA: 135] [Impact Index Per Article: 27.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2017] [Revised: 09/24/2018] [Accepted: 09/25/2018] [Indexed: 12/13/2022]
Abstract
BACKGROUND Converging lines of evidence implicate an important role for the immune system in schizophrenia. Microglia are the resident immune cells of the central nervous system and have many functions including neuroinflammation, axonal guidance and neurotrophic support. We aimed to provide a quantitative review of in vivo PET imaging studies of microglia activation in patients with schizophrenia compared with healthy controls. METHODS Demographic, clinical and imaging measures were extracted from each study and meta-analysis was conducted using a random-effects model (Hedge's g). The difference in 18-kDa translocator protein (TSPO) binding between patients with schizophrenia and healthy controls, as quantified by either binding potential (BP) or volume of distribution (VT), was used as the main outcome. Sub-analysis and sensitivity analysis were carried out to investigate the effects of genotype, ligand and illness stage. RESULTS In total, 12 studies comprising 190 patients with schizophrenia and 200 healthy controls met inclusion criteria. There was a significant elevation in tracer binding in schizophrenia patients relative to controls when BP was used as an outcome measure, (Hedge's g = 0.31; p = 0.03) but no significant differences when VT was used (Hedge's g = -0.22; p = 0.29). CONCLUSIONS In conclusion, there is evidence for moderate elevations in TSPO tracer binding in grey matter relative to other brain tissue in schizophrenia when using BP as an outcome measure, but no difference when VT is the outcome measure. We discuss the relevance of these findings as well as the methodological issues that may underlie the contrasting difference between these outcomes.
Collapse
Affiliation(s)
- Tiago Reis Marques
- Psychiatric Imaging Group, MRC Clinical Sciences Centre, Du Cane Road, London W12 0NN, UK
- Psychiatric Imaging Group, London Institute of Medical Sciences (LMS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
| | - Abhishekh H Ashok
- Psychiatric Imaging Group, MRC Clinical Sciences Centre, Du Cane Road, London W12 0NN, UK
- Psychiatric Imaging Group, London Institute of Medical Sciences (LMS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| | - Toby Pillinger
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| | - Federico E. Turkheimer
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| | - Paola Dazzan
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| | - Iris E.C. Sommer
- Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Oliver D Howes
- Psychiatric Imaging Group, MRC Clinical Sciences Centre, Du Cane Road, London W12 0NN, UK
- Psychiatric Imaging Group, London Institute of Medical Sciences (LMS), Faculty of Medicine, Imperial College London, Du Cane Road, London W12 0NN, UK
- Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, Kings College London, London, UK
| |
Collapse
|
10
|
Guma E, Rocchetti J, Devenyi GA, Tanti A, Mathieu AP, Lerch JP, Elgbeili G, Courcot B, Mechawar N, Chakravarty MM, Giros B. Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration. Sci Rep 2019; 9:7850. [PMID: 31127135 PMCID: PMC6534671 DOI: 10.1038/s41598-019-43955-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2018] [Accepted: 05/01/2019] [Indexed: 12/31/2022] Open
Abstract
Clinical research has shown that chronic antipsychotic drug (APD) treatment further decreases cortical gray matter and hippocampus volume, and increases striatal and ventricular volume in patients with schizophrenia. D2-like receptor blockade is necessary for clinical efficacy of the drugs, and may be responsible for inducing these volume changes. However, the role of other D2-like receptors, such as D3, remains unclear. Following our previous work, we undertook a longitudinal study to examine the effects of chronic (9-week) typical (haloperidol (HAL)) and atypical (clozapine (CLZ)) APDs on the neuroanatomy of wild-type (WT) and dopamine D3-knockout (D3KO) mice using magnetic resonance imaging (MRI) and histological assessments in a sub-region of the anterior cingulate cortex (the prelimbic [PL] area) and striatum. D3KO mice had larger striatal volume prior to APD administration, coupled with increased glial and neuronal cell density. Chronic HAL administration increased striatal volume in both WT and D3KO mice, and reduced PL area volume in D3KO mice both at trend level. CLZ increased volume of the PL area of WT mice at trend level, but decreased D3KO PL area glial cell density. Both typical and atypical APD administration induced neuroanatomical remodeling of regions rich in D3 receptor expression, and typically altered in schizophrenia. Our findings provide novel insights on the role of D3 receptors in structural changes observed following APD administration in clinical populations.
Collapse
Affiliation(s)
- Elisa Guma
- Integrated Program in Neuroscience, McGill University, Montreal, Quebec, H3A2B4, Canada.,Cerebral Imaging Center, Douglas Mental Health University Institute, Montreal, Quebec, H3H1R3, Canada
| | - Jill Rocchetti
- Integrated Program in Neuroscience, McGill University, Montreal, Quebec, H3A2B4, Canada
| | - Gabriel A Devenyi
- Cerebral Imaging Center, Douglas Mental Health University Institute, Montreal, Quebec, H3H1R3, Canada.,Department of Psychiatry, McGill University, Montreal, Quebec, H3A1A1, Canada
| | - Arnaud Tanti
- McGill Group for Suicide Studies, Department of Psychiatry, McGill University, Douglas Mental Health University Institute, Montreal, QC, Canada
| | - Axel P Mathieu
- Cerebral Imaging Center, Douglas Mental Health University Institute, Montreal, Quebec, H3H1R3, Canada
| | - Jason P Lerch
- Mouse Imaging Centre, The Hospital for Sick Children, Toronto, Ontario, M5T3H7, Canada.,Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, Ontario, M5G1X8, Canada.,Department of Medical Biophysics, University of Toronto, Toronto, Ontario, M5G1L7, Canada.,Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK
| | - Guillaume Elgbeili
- Department of Psychiatry, McGill University, Montreal, Quebec, H3A1A1, Canada
| | - Blandine Courcot
- Cerebral Imaging Center, Douglas Mental Health University Institute, Montreal, Quebec, H3H1R3, Canada
| | - Naguib Mechawar
- McGill Group for Suicide Studies, Department of Psychiatry, McGill University, Douglas Mental Health University Institute, Montreal, QC, Canada.,Department of Psychiatry, McGill University, Montreal, Quebec, H3A1A1, Canada
| | - M Mallar Chakravarty
- Integrated Program in Neuroscience, McGill University, Montreal, Quebec, H3A2B4, Canada.,Cerebral Imaging Center, Douglas Mental Health University Institute, Montreal, Quebec, H3H1R3, Canada.,Department of Psychiatry, McGill University, Montreal, Quebec, H3A1A1, Canada.,Department of Biological and Biomedical Engineering, McGill University, Montreal, Quebec, H3A2B4, Canada
| | - Bruno Giros
- Integrated Program in Neuroscience, McGill University, Montreal, Quebec, H3A2B4, Canada. .,Department of Psychiatry, McGill University, Montreal, Quebec, H3A1A1, Canada. .,Sorbonne University, Neuroscience Paris Seine, CNRS UMR 8246, INSERM U 1130, UPMC Univ Paris 06, UM119, 75005, Paris, France.
| |
Collapse
|
11
|
Park SW, Seo MK, McIntyre RS, Mansur RB, Lee Y, Lee JH, Park SC, Huh L, Lee JG. Effects of olanzapine and haloperidol on mTORC1 signaling, dendritic outgrowth, and synaptic proteins in rat primary hippocampal neurons under toxic conditions. Neurosci Lett 2018; 686:59-66. [PMID: 30149032 DOI: 10.1016/j.neulet.2018.08.031] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Revised: 08/13/2018] [Accepted: 08/23/2018] [Indexed: 12/15/2022]
Abstract
Recent studies have demonstrated that antipsychotic drugs may activate mammalian target of rapamycin complex 1 (mTORC1) signaling in neurons. However, the relationship between mTORC1 signaling activation and currently prescribed antipsychotic drugs remains incompletely understood. The purpose of this study was to determine whether alterations in the level of mTORC1 signaling occur after rat primary hippocampal neurons are treated with olanzapine and haloperidol under toxic conditions. Additionally, we investigated whether these drugs affect dendritic outgrowth and synaptic protein expression through the mTORC1 signaling pathway. We measured changes in mTORC1-mediated and synaptic proteins by Western blotting assay under toxic conditions induced by B27 deprivation. Dendritic outgrowth was determined by a neurite assay. Olanzapine significantly increased the phosphorylated levels of mTORC1, its downstream effectors, and its upstream activators. The increased mTORC1 phosphorylation induced by olanzapine was significantly blocked by specific PI3K, MEK, or mTORC1 inhibitors. Olanzapine also increased dendritic outgrowth and synaptic proteins levels; all of these effects were blocked by rapamycin. However, haloperidol had none of these effects. We demonstrated that olanzapine, but not haloperidol, activated the mTORC1 signaling pathway and increased dendritic outgrowth and synaptic proteins by activating mTORC1 signaling in rat primary hippocampal neurons. These findings suggest that olanzapine affects neuroplasticity by activating mTORC1 signaling.
Collapse
Affiliation(s)
- Sung Woo Park
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea; Department of Health Science and Technology, Graduate School, Inje University, Busan, Republic of Korea; Department of Convergence Biomedical Science, College of Medicine, Inje University, Busan, Republic of Korea
| | - Mi Kyoung Seo
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea
| | - Roger S McIntyre
- Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Rodrigo B Mansur
- Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada
| | - Yena Lee
- Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Ontario, Canada
| | - Jae-Hon Lee
- Department of Psychiatry, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea
| | - Seon-Cheol Park
- Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan, Republic of Korea
| | - Lyang Huh
- Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan, Republic of Korea
| | - Jung Goo Lee
- Paik Institute for Clinical Research, Inje University, Busan, Republic of Korea; Department of Health Science and Technology, Graduate School, Inje University, Busan, Republic of Korea; Department of Psychiatry, College of Medicine, Haeundae Paik Hospital, Inje University, Busan, Republic of Korea.
| |
Collapse
|
12
|
Ghanbarizadeh SR, Dinpanah H, Ghasemi R, Salahshour Y, Sardashti S, Kamali M, Khatibi SR. Quetiapine versus Haloperidol in Controlling Conversion Disorder Symptoms; a Randomized Clinical Trial. EMERGENCY (TEHRAN, IRAN) 2018; 6:e47. [PMID: 30584563 PMCID: PMC6289155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
INTRODUCTION About 5% of visits to emergency departments are made up of conversion disorder cases. This study was designed with the aim of comparing the effectiveness of quetiapine and haloperidol in controlling conversion disorder symptoms. METHODS The present single-blind clinical trial has been performed on patients with conversion disorder (based on the DSM-IV definition) presenting to emergency department of 9-Day Hospital, Torbat Heydariyeh, Iran, from January 2017 until May 2018. RESULTS 73 patients were allocated to haloperidol and 71 to quetiapine group. Mean age of these patients was 32.03 ± 12.80 years (62.50% female). Two groups were similar regarding the baseline characteristics. Within 30 minutes, 90.41% of haloperidol cases and 91.55% of quetiapine cases were relieved (p=0.812). The most common side effects after 30 minutes were extrapyramidal symptoms (9.59%) in the haloperidol group and fatigue and sleepiness (7.04%) in the quetiapine group. Extrapyramidal symptoms was significantly higher than the quetiapine group (p=0.013). CONCLUSION The results of the present study showed that although quetiapine and haloperidol have a similar effect in relieving the patients from conversion disorder symptoms, the prevalence of extrapyramidal symptoms is significantly lower in the group under treatment with quetiapine. Therefore, it seems that quetiapine is a safer drug compared to haloperidol.
Collapse
Affiliation(s)
- Saeed Reza Ghanbarizadeh
- Department of urology, 9-Day Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
| | - Hossein Dinpanah
- Emergency Department, 9-Day Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
| | - Reza Ghasemi
- Department of Cardiology, 9-Day Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
| | - Yaser Salahshour
- Department of Pediatrics, 9-Day Hospital, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran.
| | - Samaneh Sardashti
- Master of Nursing, Faculty member, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| | - Mostafa Kamali
- Department of Health Information Technology, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| | - Seyed Reza Khatibi
- Department of Epidemiology, Faculty of Health, Iran University of Medical Sciences, Tehran, Iran.,Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| |
Collapse
|
13
|
|
14
|
Crum WR, Sawiak SJ, Chege W, Cooper JD, Williams SC, Vernon AC. Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: A longitudinal in vivo MRI study. Brain Behav Immun 2017; 63:50-59. [PMID: 27940258 PMCID: PMC5441572 DOI: 10.1016/j.bbi.2016.12.008] [Citation(s) in RCA: 58] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2016] [Revised: 11/07/2016] [Accepted: 12/07/2016] [Indexed: 02/08/2023] Open
Abstract
Genetic and environmental risk factors for psychiatric disorders are suggested to disrupt the trajectory of brain maturation during adolescence, leading to the development of psychopathology in adulthood. Rodent models are powerful tools to dissect the specific effects of such risk factors on brain maturational profiles, particularly when combined with Magnetic Resonance Imaging (MRI; clinically comparable technology). We therefore investigated the effect of maternal immune activation (MIA), an epidemiological risk factor for adult-onset psychiatric disorders, on rat brain maturation using atlas and tensor-based morphometry analysis of longitudinal in vivo MR images. Exposure to MIA resulted in decreases in the volume of several cortical regions, the hippocampus, amygdala, striatum, nucleus accumbens and unexpectedly, the lateral ventricles, relative to controls. In contrast, the volumes of the thalamus, ventral mesencephalon, brain stem and major white matter tracts were larger, relative to controls. These volumetric changes were maximal between post-natal day 50 and 100 with no differences between the groups thereafter. These data are consistent with and extend prior studies of brain structure in MIA-exposed rodents. Apart from the ventricular findings, these data have robust face validity to clinical imaging findings reported in studies of individuals at high clinical risk for a psychiatric disorder. Further work is now required to address the relationship of these MRI changes to behavioral dysfunction and to establish thier cellular correlates.
Collapse
Affiliation(s)
- William R. Crum
- Department of Neuroimaging Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, UK
| | - Stephen J. Sawiak
- Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, UK
| | - Winfred Chege
- Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, UK
| | - Jonathan D. Cooper
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, UK
| | - Steven C.R. Williams
- Department of Neuroimaging Institute of Psychiatry, Psychology and Neuroscience, King’s College London, De Crespigny Park, London SE5 8AF, UK,MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK
| | - Anthony C. Vernon
- Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, UK,MRC Centre for Neurodevelopmental Disorders, King's College London, London SE1 1UL, UK,Corresponding author at: Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, Maurice Wohl Clinical Neuroscience Institute, 5 Cutcombe Road, London SE5 9RT, UK.Department of Basic and Clinical NeuroscienceInstitute of PsychiatryPsychology and NeuroscienceKing’s College LondonMaurice Wohl Clinical Neuroscience Institute5 Cutcombe RoadLondonSE5 9RTUK
| |
Collapse
|